3 results about "Aneurysm dissecting" patented technology

Various concepts involve an iliac bifurcation prosthesis extending a length between the proximal and distal ends, which bifurcates from the main flow channel into two flow channels. Various concepts also involve methods for deploying an in-situ prosthesis system to treat aortic aneurysms, including deploying the iliac bifurcation prosthesis into the ipsilateral leg of the bifurcation main prosthesis or into the contralateral opening of the bifurcation main prosthesis.

The application relates to the technical field of biological medicine, and discloses an engineered exosome, a preparation method and purposes thereof. The method comprises the following steps: introducing an exogenous nucleic acid coding a human TIMP3 protein into endothelial progenitor cells to construct engineered cells, and obtaining exosomes by separating and purifying the supernatant after culture. The engineered exosome is secreted by the endothelial progenitor cells and is efficiently loaded with the TIMP3, and has both cell homing characteristics and protease inhibition functions. The exosome can significantly inhibit matrix metalloproteinase 3 (MMP3) activity, reduce extracellular matrix degradation, and improve the structural stability of a blood vessel wall. The application provides a novel and efficient cell-free delivery strategy for treating aortic dissection, aneurysm and other vascular remodeling diseases.

A pharmaceutical composition for preventing an aortic aneurysm is provided including a medium chain fatty acid as a main component, which has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.